BreathID 13C-Methacetin Breath Test for Detecting Cirrhosis

PHASE3CompletedINTERVENTIONAL
Enrollment

414

Participants

Timeline

Start Date

August 31, 2008

Primary Completion Date

September 30, 2009

Study Completion Date

September 30, 2009

Conditions
Chronic Liver Disease
Interventions
DEVICE

c13 methacetin solution with breath analyzer

Carbon 13 methacetin 75mg dissolved in 150 ml is given to the subject and metabolism is measured by a breath analyzer after decomposed by the liver

Trial Locations (11)

19104

University of Pennsylvania Health System, Philadelphia

22042

Inova Helath System, Falls Church

29435

Medical University of South Carolina, Charleston

44195

Cleveland Clinic, Cleveland

48202

Henry Ford Health Sytem, Detroit

77030

St Luke's Episcopal Hospital, Baylor College of Medicine, Houston

90048

Cedars Sinai Medical Center, Los Angeles

93000

Hadassah Medical Center, Jerusalem

23298-0341

Virginia Commonwealth University Medical Center, Richmond

Unknown

Soroka Medical Center, Beersheba

Carmel Medical Center, Haifa

Sponsors
All Listed Sponsors
lead

Meridian Bioscience, Inc.

INDUSTRY